We therefore propose that AR may be clinically useful as a target to achieve tumor-specific OXPHOS inhibition and FDA-approved anti-AR drugs including enzalutamide and the older generation bicalutamide have been shown to be tolerated in women (53, 54). This evidence concerns the gene AR and neoplasm.